For research use only
| Cat No. | ABC-X0193C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The human CCDC6-RET BAF3 Cell Line supports RET fusion research, aiding in the study of oncogenic signaling and screening of RET pathway inhibitors.
Human CCDC6_RET BAF3 Cell Line is a murine pro-B cell model stably expressing the CCDC6-RET fusion oncogene via lentiviral vector delivery. Expression is validated by qRT-PCR, and cultures are maintained at low passage (<P20). Target CCDC6-RET is a recurrent fusion in papillary thyroid carcinoma and lung adenocarcinoma. It drives RAS-MAPK pathway activation and cellular transformation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0193C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model supports RET fusion-targeted drug testing, mechanistic studies, and resistance mechanism characterization in oncogenic RET-driven cancers.